Intensive Lipid Lowering Treatment in Non-ST-elevation Acute Coronary Syndrome (NSTE-ACS) Patients
NCT ID: NCT01040936
Last Updated: 2011-06-15
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE4
300 participants
INTERVENTIONAL
2010-05-31
2011-11-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Intensive Statin Treatment in Chinese Coronary Artery Disease Patients Undergoing PCI
NCT01293097
Intensive Statin Therapy in PCI Patient With Acute Coronary Syndrome
NCT01372839
The Clinical Effect of Intensive Statin Therapy in STEMI Patients Before Emergency PCI
NCT01334671
Intensive Statin Treatment for STEMI Patients Undergoing Primary PCI
NCT01033058
Sequential Therapy of Atorvastatin Improve Outcomes of ST-elevated Acute Myocardial Infarction
NCT01997294
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
conventional group
patients will be treated by atorvastation 20mg/d after randomization, and continued for one year.
Atorvastatin
patients admitted for Non-ST elevation ACS will be treated by atorvastatin 20md/d for one year
intensive group
patient will be loaded with 80mg atorvastatin, continued by atorvastatin 40mg/d for 30d, then receive atorvastatin 20mg/d for the following 11 months.
Atorvastatin
patients admitted with Non-ST elevation ACS will be loaded with atorvastatin 80mg once, continued with 40mg/d for 30d, then change to 20mg/d, as a regular dose in China
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Atorvastatin
patients admitted for Non-ST elevation ACS will be treated by atorvastatin 20md/d for one year
Atorvastatin
patients admitted with Non-ST elevation ACS will be loaded with atorvastatin 80mg once, continued with 40mg/d for 30d, then change to 20mg/d, as a regular dose in China
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* age≥18y and under 75y
* diagnosed as non-ST elevation acute coronary syndrome, including unstable angina and non-ST elevation myocardial infarction
* willing to receive the coronary angiography and potential PCI therapy
Exclusion Criteria
* stable angina or ST elevation myocardial infarction
* without informed consent
* abnormal liver function before randomization, (AST，ALT≥3ULN)
* active hepatitis or muscular disease
* impaired renal function with serum creatinine level \> 3mg/dl
* impaired left ventricular systolic function with LVEF\< 30%
* participating in other studies
* non-PCI treated patients after coronary angiography will be washed out
18 Years
75 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Shanghai Jiao Tong University School of Medicine
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Shanghai Jiao Tong University
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Wei Feng Shen, MD, PhD
Role: PRINCIPAL_INVESTIGATOR
Shanghai Jiao Tong University School of Medicine
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Ruijin Hospital, Dept. of Cardiology
Shanghai, Shanghai Municipality, China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
RJH-2009
Identifier Type: OTHER
Identifier Source: secondary_id
RJH-091228
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.